|
|
|
- みがね えいさか
- 6 years ago
- Views:
Transcription
1
2
3 RNA ATP BH4 PAH PAA PPA PLA T3,T4 PheTyr Phe 8PKU
4 PKUMSUD OTC, CPS PDH,MELAS MCAD () Smith-Lemli-Opitz, XP,MRI (CK, MR MR 1st 1st GC/MS GC/MS ( ) 2nd 2nd 3rd 3rd 4th 4th
5 I, III I, III FDPase FDPase CDG CDG 24 (+) (-) etc - etc (+) (-) etc HHH (+) (-) OTC CPS I NAGS (+) (-) NH3 / () (+) GH TSH/FT st 1st GC/MS GC/MS ( ) 2nd 2nd 3rd 3rd 4th 4th
6 (+) (-) 24 (-) (+) 2nd 1st 3rd GC/MS ( ) 4th (+) (-) etc HHH - etc etc OTC (+) (-) CPS I NAGS 1st 3rd 2nd GC/MS ( ) 4th
7 CTLN2) NICCD) - CTLN2 Na cm 7cm 1st 1st GC/MS GC/MS ( ) 2nd 2nd 3rd 3rd 4th 4th NH3 / () (+) GH TSH/FT4 0.3 I, III I, III FDPase FDPase CDG CDG
8 1 7 AEEGMRI B -2.5SDA Hb 9.5g/dlPlt 6.8 Gaucher / 290/kg 8 1st 2nd 3rd GC/MS ( ) 4th Copper transporting ATPase(ATP7B) Fabry TSH, 17OHP µ
9 Fabry Fabry / MPS QOL 6.
10
11 References 1. Miyahara H, Korematsu S, Nagakura T and Izumi T. Efficasious difference of spirometry between a fluticasone MDI and a DPI for pediatric asthma. Pediatr Int 2008;50: Group (from 90 MDI-S 80 to 70 DPI) Group (from 100 DPI 80 to 60 MDI-S) Total (Group ) %FEV 1.0 (%) Pre MDI-S DPI Pre DPI MDI-S ;4: p< p= p=0.014 Pre MDI-S DPI PEAK study Guilbert TW et al. N Engl J Med 2006;354: fluticasone 1 PAC study Bisgaard H et al. N Engl J Med 2006;354: double-blind, control study 32budesonide 3 IFWIN study Murray CS et al. Lancet 2006;368: , randomised, double-blind, control study fluticasone 5
12 2. RS11 (Stein RT et al. Lancet 1999;354: ) 24%11% (Harju TH et al. Thorax 2006;61: ) IL8 RSVIL8 (Friedland JS. Res Virol 1996;147: ) IL8 (Thanawonqnuwech R et al. Vet Immunol Immunopathol 2001;79: ) IL8 IL8 (Norzila MZ et al. Am J Respir Crit Care Med 2000;161: ) IgE IgEIL8 (Gounni AS et al. FASB J 2001;15: ) IL8polymorphism (Puthothu B et al. Clin Mol Allergy 2006;4:2) IL8 (Kikuchi I et al. Am J Respir Cell Mol Biol 2006;34: ) IL4 2 T (Th2) IL5 3. IgE B IL8 IgE References ;66: ;44: LF/HF HF PER (msec 2 /Hz) LF/HF p< (msec 2 /Hz) HF (L/min) PER 350 p<0.01 p<
13 % (114) 62% (189) % 2-4 IgE IL4 2 T (Th2) B IL5 Bao B et al. Am J Physiol Endocrinol Metab 2003;285:E Th1 Kitamura H et al. Nat Immunol 2006;7:971-7 Li H et al. J Biol Chem 2007;282: MHC class Metz CH et al. Nutrition 2007;23: Th2Th1 T Infection Naïve helper T cell Th1 (TB, bacteria) 1 B cell IgG 5. Allergen (mite, food) Th2 B cell IgE Reference Korematsu S, Miyahara H, Nagakura T, Suenobu S and Izumi T. The theophylline-associated seizures and their clinical characterizations. Pediatr Int 2008;50:95-95.
14 Table 1. The list of pediatric patients with TAS Patient No Age (year) Sex Family history FC Epilepsy Severity of Asthma Clinical findings on first sz Serum The concentration (g/ml M a Intermittent N.E M Intermittent F + - Intermittent M + - Moderate N.E. + 1 b 5. 4 M - + Intermittent F - - Intermittent M Moderate F ++ - Intermittent Fever (38) FC: febrile convulsion, sz: seizure, N.E.: not examined a: Epilepsy, treated with antiepileptic drugs, b: Benign childhood epilepsy with centrotemporal spikes Table 2. The neurological findings and outcomes in eleven patients with TAS outcome Patient Seizure EEG SPECT MRI No type medication seizure other neurological findings 1. GTS Lt. hemisphere Lt. T hypo. U.R. - - TIQ 89, VIQ 85, PIQ 96 slow wave 2. Rt. unilateral sz. Lt. hemisphere low volt. act. N.O. Lt. T T2-high CBZ - cessation 3. GTS Diffuse slow Lt. T hypo. U.R GTCS Diffuse slow N.O. U.R. 5. CPS with 2nd T spikes N.O. U.R. - - generalization CPS with 2nd CBZ Rt. hemisphere Rt. F hypo. U.R. - generalization cessation slow wave 7. Lt. hemisphere GTCS slow wave N.O. N.O. - - Lt. unilateral 8. dominant sz. Rt. F,C,P spikes N.O. Rt. venous - - angioma Rt: right, Lt: left, sz: seizure, epi: epilepsy, GTS: general tonic sz, GTCS: general tonic clonic sz, CPS: complex partial sz, volt: voltage, act: activity, hypo: hypoperfusion, HHE: hemiconvulsion hemiplegia and epilepsy, CBZ: carbamazepin, F: frontal, T: temporal, P: parietal, O: occipital, FC: febrile convulsion, N.O.: not obtained, U.R.: unremarkable CBZ - HHE, TIQ 53, VIQ 64, PIQ 58 Hyperkinetics, DQ65 6. TIQ 112, VIQ 111, PIQ 110 TAS Yarnell PR et al. Neurology 1975;25:819 / Mori H et al. J Neurol Neurosurg Psychiatry 1992;55:466 Dunn DW et al. Neuropediatrics 1991;22:24 Tchekalarova J et al. Brain Res Bull 2000;52:13 TAS Magnussen I et al. Acta Neurol Scand 1977;55:131 Bowton DL et al. Am Respir Crit Care Med 1994;150:1002 Bartel PR et al. Am J Clin Nutr 1994;60:93 pyridoxal Bonfiglio MF et al. Pharmacotherapy 1996;16:1166 adenosinebenzodiazepine Gulati K. Pharmacol Biochem Behav 2004;82:241 free radical T References 1. Korematsu S, Tanaka Y, Hosoi S et al. C8/119S mutation of major mite allergen Derf-2 leads to degenerate secondary structure and molecular polymerization and induces potent and exclusive Th1 cell differentiation. J Immunol 2000;165: Korematsu S, Tanaka Y, Nagakura T, Minato N and Izumi T. Human T cells modurate the mite allergen-specific Th2-skewed immunity. Clin Exp Allergy 2007;37: T 2Derf2Th2 Th1 IL-4 IFN- (pg/ml) Th2Th1 IgE (Korematsu S et al. J Immunol 2000;165:2895)
15 IgE SS C8/119S Derf2 IL IFN- SS Th1 C8/119S (Korematsu S et al. J Immunol 2000;165:2895) C8/119STh1 IgE Derf2 C8/119S B Th2 DC M IL6 B Th1 DC M TNF Infection (TB, bacteria) Naïve helper T cell Allergen (mite, food) Th1 Th2 (Shirakawa T et al. Science 1997;275:77) B cell B cell IgG IgE Th1Treg Th2 in vitro BCGTh1T Th Derf22BCG Derf2Th2BCGTh1 T Derf2Th2BCGTh1T Th2IL4
16 Derf2 (cpm: x 1,000) (g/ml) BCG (cpm: x 1,000) (%) (cpm: x 1,000) (M) Derf2 BCG BCG Derf2 A Derf2Th2 B Derf2Th2 A BCGTh1 C BCGTh1 D BCGTh1 A T B T C T D T T IL10 (IL4: pg/ml) n.d. n.d. n.d. n.d. n.d. n.d. n.d (IFN: pg/ml) Derf2Th2T (IL4: pg/ml) Derf2 (IFN: pg/ml) (IL4: pg/ml) (g/ml) (M) 0 (IFN: pg/ml) Th2 TT5% Th2 T Th2 Th2 Th2 T Th2 * Th2 Th2 T T T Th2 Th2 T T T T T T T T T T * Tanaka Y et al. Nature 1995;375:155 carry over
17 1 4(100cm) = ICP growth model
18 LH Orchid meter
19
20
21 Growth potential () Target height 75cm 50cm 10kg 5kg 1 2
22 6 3
23 SD 119 P:2 PH:1-2 Testis:7-8ml g
24 Arm span 2 septo-optic-dysplaisia Karyotype Prenatal* Postnatal 45,X 134 (64%) 162 (47%) 45,X/46,XX 45 (22%) 59 (17%) 45,X/46,X,I (Xq); 45,X/46,X,I (Xq)/47,X,I(Xq),I(Xq) 9 (4%) 41 (12%) etc 45,X/46,X,del(X); 46,X,del(X) 15 (7%) 27 (8%) 45,X/46,XX/47,XXX; 45,X/47,XXX; 5 (2%) 16 (5%) 45,X/46,XX/47,XXX/48,XXXX 45,X/46,X,r(X) 1 (<1%) 20 (6%) 45,X/46,XY 10 (3%) Others with Y material 11 (3%) Critical regions for TS phenotypes on the X chromosome Phenotype Stature, skeletal anomalies Stature, gonadal failure, minor physical features Viability Gonadal failure X Gene (candidate) p q SHOX (ZFX) (USP9X) (RPS4X) (DIAPH2) =
25 Medical conditions common in TS Organ/System Feature Frequency (%) Heart Congenital cardiac 30 problems Skeleton Bone age retardation 85 Reduced bone mineral 5085 density Kidneys Renal abnormalities 30 Endocrine Glucose intolerance 30 Thyroid dysfunction 1030 Ears Middle ear infection 60 Hearing defects 30 Psychosocial problems Emotional immaturity and learning problems Up to 40% (Hypophyseal dysplasia) Hypophyseal dysplasia Prader-Willi IGF-1C TSHfT3fT4
26 L-dopa
27
28
表1.eps
Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol
medicaljournal8.pdf
Medical Journal of Aizawa Hospital Vol. 8 (2010) Key words Neuropsychopharmacology Neuroscientist Curr Opin Neurol Clin Rehabil J Neurol Neurosurg Psychiatry J Neurol Neurosurg Psychiatry Lancet
Medical Journal of Aizawa Hospital Medical Journal of Aizawa Hospital Vol. 8 (2010) Key words Neuropsychopharmacology Neuroscientist Curr Opin Neurol Clin Rehabil J Neurol Neurosurg Psychiatry
/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1
11 1 -------------------- 19 205.117/205.128 14/15 205.126A/205.126B 16/17 COPD 18mcg COPD 11.1 11.1.1 COPD 100 19 205.227 COPD 1 FEV1.0 %FEV1.0 70% 1 FEV1.0 / FVC 70% 2 1 200 3 40 COPD 1 10mg ACE 1 1
19 8 1970 20 10 4 1
19 8 1970 20 10 4 1 IgE 1960 % 1970 20%, 1990 40% 1998 70% 20 IgE 21 90% IgE IgE (%) 70 60 50 40 30 20 10 0 1970 1975 1980 1985 1990 1995 2000 2005 1. 2005 10 2 30 IgE 2. 3 1. B IgE T IgE IgE IgE 2 T IgE
日本皮膚科学会雑誌第122巻第2号
J Dermatol Sci Vitam Horm NEnglJMed Lancet J Clin Invest Antitoxid Redox Signal Diabetes Metab Res Rev Diabetes Care Diabet Med Diabetes care Diabetes Care J Foot Ankle Surg Wound Repair Regen Lancet Foot
2001 2003 2005 2006 2007 2008
2001 2003 2005 2006 2007 2008 60 etc. http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm 23.5% 2.8% 2.8% 3.4% 30.3% 9.9% 11.5% 15.8% AAN 65
437“ƒ
et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer
The Heart Healthy Tocotrienol Complex Tocomin SupraBio
The Heart Healthy Tocotrienol Complex Tocomin SupraBio The Heart Healthy Tocotrienol Complex Tocomin SupraBio 1. Fact Sheet No. 317; World Health Organization (WHO), 2007 2. LLOYD-JONES D. et al. Circulation
body size no effect mechanical stress GH-IGF1 system + no effect? collagen production of fibroblasts + receptor + + Ia, Ib, II aldosterone renin angiotensin system Mechanical and Endocrinological
et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology
37 Recommendations for the Management of Moyamoya Disease A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) Research on intractable diseases of the
特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書（案）
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
1. Prader, A., Labhart, A. and Willi, H.: Ein Syndrom von Adipositas, Kleinwuchs, Kryptor- kysmus und Oligophrenie nach Myotonieartigem Zustand in Neugeboren, Schweiz. Med. Wocheschr., 86: 1260-1261, 1956.
AUTONOMIC FUNCTIONAL STATE IN RENAL TUBERCULOSIS REPORT III. SERUM CHOLINESTERASE ACTIVITY IN RENAL TUBERCULOSIS Sanai Yamamura The Department of Urol
AUTONOMIC FUNCTIONAL STATE IN RENAL TUBERCULOSIS REPORT III. SERUM CHOLINESTERASE ACTIVITY IN RENAL TUBERCULOSIS Sanai Yamamura The Department of Urology, Kumamoto University College of Medicine (Director:
Various function and toxicity of iron Key words 1) Hentze, M. W. et al: Cell, 117, 285-297 (2004) 2) Ganz, T.: Blood, 102, 783-788 (2003) 3) Nemeth, E. et al.: Science, 306, 2090-2093 (2004) 4) Hentze,
Ⅰ. Statistics Concerning Health Birthweight (1) Birthweight by year (2) Mean birthweight by prefecture, 2007-1997 (3) Percentage of births under 2,500g by prefecture, 2007-1997 Sex Ratio (4) Sex ratio
説明書82：妊娠と抗てんかん薬★★.PPT
Preg-82 2002.8 Ⅰ. Nakane Y et al.: Multi-institutional study on the teratogenecity and fetal toxitity of antiepileptic drugs: A report of a collabolative study group in Japan. Epilepsia, 21; 663-680,1980.
8 20 symptom free 2 NEJM Clinical Practice fluticasone 1 2 fluticasone IgE 100U/ml 1819 Bostock 1 A Mycobacterium Toxoplasma
The Lancet, vol 378, Dec.17/24/31,2011 Alexander N Greiner USA Peter W Hellings, Guiseppina Rotiroti Glenis K Scadding The Lancet, Dec. 17/24/31, 2011 http://www.allergy.go.jp/allergy/guideline/04/index.html
CAR-T実施
Building a Clinical CAR-T Program - Jichi Medical University Experience l l l Anti-CD3/28 mabs & IL-2: 29% Anti-CD3/28 beads: 66% Retroviral: 41% Lentiviral: 54% T-Flasks: 22% Static Culture Bags: 35%
山梨大学医科学雑誌23-2
23 2 21 31 2008 context bias executive function cognitive neuroscience Learning Disorders; LD Attention-Deficit/Hyperactivity Disorder; ADHD 6.3 409-3898 1110 2008 2 15 2008 2 25 17 4 1 1,2 3,4 22 1 feeling
Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents
D 012 Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents DATA : 1 DATA : 2 3 DATA : UNGITEC 1 1 DATA : 20pg/mL 1020pg/mL 10pg/mL (cut off 20pg/mL) 90.2%(37/41) 100%(85/85) 96.8%(122/126)
1) van Meer, G., Op den Kamp, J. A.: J. Cell. Biochem., 19, 193-2040982) 2) Gaffet, P., Bettache, N., Bienvenue, A.: Biochemistry, 34, 6762-6769(1995) 3) Sims, P. J., Wiedmer, T.: Thromb. Haemost., 86,
第122号.indd
-1- -2- -3- 0852-36-5150 0852-36-5163-4- -5- -6- -7- 1st 1-1 1-2 1-3 1-4 1-5 -8- 2nd M2 E2 D2 J2 C2-9- 3rd M3 E3 D3 J3 C3-10- 4th M4 E4 D4 J4 C4-11- -12- M5 E5 J5 D5 C5 5th -13- -14- NEWS NEWS -15- NEWS
1) Michaelis L. Biochem Z., 59, 78, 1914. 2) Ferris H. C. Dent. Cosmos Phila., 63, 10, 93, 1921. 3) Bloomfield A. L. Bull Johns Hopk. Hosp. Bait., 31, 118, 1920. 4) Starr H. C. J. Biol. Chem. Bait., 54,
A Clinical and Electroencephalographic Study of Myoclonic Epilepsies in Infancy and Early Childhood Part 1. On the Classification Key Words: myoclonic
A Clinical and Electroencephalographic Study of Myoclonic Epilepsies in Infancy and Early Childhood Part 1. On the Classification Key Words: myoclonic epilepsy, classification, infancy and early childhood,
Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST
Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST 13) Danaeus, A., Johansson, S. G. O., Foucard, T. & Ohman, S.: Clinical and immunogical aspects of food allergy in childhood.
untitled
COLAK Mehmed 11000 305 305 180 10000 9000 8000 160 140 120 7000 100 6000 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 80 GH IGF-1 GH GH 5 4 3 2 1 0 2 3 4 5
drug development Toshimi Michigami, E-mail : michigami@mch.pref.osaka.jp Keiichi Ozono, E-mail : keioz@ped.med.osaka-u.ac.jp The progress in the research on vitamin D 1) McCollum, E. V. et al.:
:,, : - 7 -
31 ~ ~ - 6 - :,, : - 7 - (),,,,,,; ~ ~ *1 *2 6,,,~,,~ - 8-32 ,, ( );( ),,,,,, ~ ~ ~,,,, (),,,,, - 9 - 33 ~*~ ~~ ~, ~ ~ ~ ~ ~, ~~,,,, - 10 - BCG () g ) BCG BCG,, 34 ,,,, (),,,,,,,,,,,,,, () ( 3 90 [7 6
/‚“1/ŒxŒ{‚×›î’æ’¶
60 1 pp.3-8 2010 1. H1N1 1) 2) 3) 4) ERATO 2009 H1N1 21 H1N1 HA PB2 2009 3 Pandemic H1N1 2009 WHO 6 11 21 2009 11 2010 4 21 H1N1 H1N1 2009 4 15 CDC 108-8639 4-6-1 TEL: 03-5449-5281 FAX: 03-5449-5408 E-mail:
小児内分泌学会-03-プログラム.indd
10 2 8 30 9 55 SOP 2 P-044 P-045 2 P-046 :Frasier 1 1 1 1 1 1 2 2 1 1 2 P-047 GH 1 1 2 2 2 2 2 1 2 P-048 Bartter 1 1 1 1 2 1 2 P-049 SD IGF-1 GHD P-050-2SD GHD 1 2 2 2 1 2 P-051 GHD 1,2 1 1 1 1 1 2 2 3
Sulfonylurea Receptors Pancreatic Type: SUR1 Cardiac Type: SUR2A Smooth Muscle Type: SUR2B Kir Channels uka-rp-1/kir6.1 BIR/Kir6.2 1) Ho K, et al : Cloning and expression of an inwardly rectifying ATP-regulated
5 CSF 6 CSF 7 CSF CSF CDV CDV GFAP CSF Pandy test NSE MBP LDH mu/ml 0-5 /µl AST mu/ml CK mu/ml <25 mg/dl<45 mg/dl GLU
CT MRI CSFCSF CSF CSF CSF CSF CSF (cisternal puncture) CSF 20-23G 90 (20-23G) : CSF
中高齢者の健康・いきいきライフスタイルづくり調査
1 -- -- 10 11 12 1998-2000 Exercise: A Guide from the National Institute on Aging 1 61-80 26 T PHA Streptoccocal enterotoxin ASEA (IL-2; Th1 ) IL-4Th2 IgE T T - Bcl-2 Fas T PHA SEA IL2 T PHA SEA IL2
日本化学療法学会雑誌第59巻第5号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S.
1) Waardenburg PJ : A new syndrome combining developmental anomalies of the eyelids, eyebrows and nose root with pigmentary defects of the iris and head hair and with congenital deafness. Am J Hum Genet
No21Vol1.indd
( ): - PSA Shojiro Kano Head, Working Group of PSA Testing Standardization Committee (PSA) PSA PSA JCCLS PSA A PSA B PSA PSA Wang PSA FDA Hybritech Tandem-R PSA PSA PSA PSA - (ACT) - (AMG) ACT (PSA-ACT)
65-6 小泉・谷所・野村・楠本.pwd
CSA p r p r 5N 20N 5N 10N 15N 20N Komiya et al 0kgf 25 kgf MRI 50M 171.1 5.15 cm, 64.3 7.78 kg, 26.13 1.420 cm Oldfield The Edinburgh Inventory LEFT RIGHT RIGHT RIGHT LEFT LEFT RIGHT Oldfield Laterality
理学療法科学シリーズ臨床運動学第6版サンプル
μ μ μ μ μ α μ 1) Appell HJ: Skeletal muscle atrophy during immobilization. Int J Sports Med 7: 1-5, 1986. 2) Bohannon RW: Make tests and break tests of elbow flexor muscle strength.
Novel chemical mediators in the resolution of inflammation Charles N. Serhan Key words E-mail : marita@nih.go.jp Charles N. Serhan Brigham & Women's Hospital/Harvard Medical School 1) Serhan, C. N.,
CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation
CHEMOTHERAPY CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation CHEMOTHERAPY Table 1 Preliminaly test of AM- 715 1): Mean } SD *: Significant difference
ッ ー ー ー() () 2.5 () () 21 1) -1 2) -2 10 m 5 7 23 6 1)2) 3) -1-2 H23.4.25 -15-20 4 75 5 1) -1 (5) (3) (3) (2) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) 1) ( 23 6 8 ) 2) 22 3)
E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
Diagnosis of Dementia: Update
10 C A 1 2 Normal SMI MCI Early Dementia B Moderate Dementia 3 Severe Dementia 4 5 D AD, VD, FTD, DLB, PDD Depression Dementia d/t GMC Modifiable risk factors and preventive factors for dementia 6-5 -
中高生を中心とした子供の睡眠習慣に関する科学的知見の整理分科会 第1回 配付資料その2
0% 20% 40% 60% 80% 100% 0% 20% 40% 60% 80% 100% 0% 20% 40% 60% 80% 100% 0% 20% 40% 60% 80% 100% (%) 80 60 40 20 0 1.1 0.7 71.1 54.1 ~21:00 21:00 ~21:30 2*** 32.6 22.8 22:00 ~22:30 8.9 3.4 1.6 3.7 23:00
1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
8 8.1 Lieberman; db Kisilevsky; 1989 Hartikainen; db 90 db Ando & Hattori; 1973 Suzuki & Kabuto; ,000 2,500g 13 Lagers
8 8.1 Lieberman; 1975 100 105 db Kisilevsky; 1989 Hartikainen; 1994 78 db 90 db Ando & Hattori; 1973 Suzuki & Kabuto; 1978 713 40,000 2,500g 13 Lagerstrom et al.; 1991 Rantakallio; 1985, McDermott et al.;
untitled
Contents 1. 2 2. 3 3. 7 4. 9 5. 14 6. 15 7. 17 8. 19 9. 21 1. growth hormone deficiency : GHD10,00015,000 2 2. 03 1GH T3T4 1 GHRHGHIH -CIGF-1 -CIGF-1 3 1 GHRH GHIH GH TSH LHFSH -C IGF-1 -C IGF-1 T3T4 4
untitled
CoQ10 CoQ10 CoQ10 CoQ10 CoQ10 (A CoQ10 CoQ10 B CoQ10 CoQ10 C CoQ10 CoQ10 CoQ10 QOL CoQ10 QOL CoQ10 CoQ10 CoQ10 CoQ10 14 還元型 CoQ10 の摂取はインフルエンザウイルス感染に対する予防効果を示す CoQ1050CoQ10 CoQ1080CoQ10 Åberg et al., Arch
24 RS 24 RSRespiratory Syncytial Virus RS BPD24 24CHD RS RS BPD CHD
Immunocompromised Children 24 RS24 24 RS 24 RSRespiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 1 RS 28 2935 12 6 RS BPD 246 1 1 CHD 24 24 24 2 RS [1] [1.1] RS 24 RS T DiGeorge Wiskott- Aldrich
1) Ming J E, Muenke M. Holoprosencephaly; from Homer to Hegehog. Clin Genet 1998; 53: 155-63. 2) Cohen M M Jr. Perspectives on holoprosencephaly: Part I. epidemiology, genetics, and syndromology. Teratology
(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12
(1)...109 (2)...110 (1) 28...111 (2) 28...113 (1) Seg...115 (2) Seg...117 (3) Seg...119 (4) Seg...120 (1)...122 (2)...122 (3) ( )...126 (1) (PCA)...127 (2) Draize...128 (1) Ames...129 2 in vitro...132
CRA3689A
AVIC-DRZ90 AVIC-DRZ80 2 3 4 5 66 7 88 9 10 10 10 11 12 13 14 15 1 1 0 OPEN ANGLE REMOTE WIDE SET UP AVIC-DRZ90 SOURCE OFF AV CONTROL MIC 2 16 17 1 2 0 0 1 AVIC-DRZ90 2 3 4 OPEN ANGLE REMOTE SOURCE OFF
本文／ＹＡ９２５５Ｃ
pp. E- -SH X in vitro in vivo -SH Structure-based drug development and medical biological application of cathepsin specific inhibitors Nobuhiko Katunuma Institute for Health Sciences, Tokushima Bunri University,Nishihamabouji,
118 Dementia Japan Vol. 31 No. 1 January 2017 表 1. DLB に対して mect を行った先行研究 Rasmussen K 2003 USA Japan Japan Japan Japan 1 2
Dementia Japan 31 : 117-124, 2017 117 症例報告 要旨 1. はじめに 70 1 modified electroconvulsive therapy ; mect mect Modified electroconvulsive therapy in dementia with Lewy bodies with drug - resistant psychiatric
_06.indd
30, 35-39, 2010 0.15% 1 C 40 20 1 cm 5 mm WBC 9,400, RBC 259 10 4, Hb 8.5 g/dl, Ht 25.5%, Plt 29 10 4, BUN 116 mg/dl, Cr 7.9 mg/dl, 125 mg/dl, HbA1c 4.3%, ft3 1.97 pg/ml, ft4 1.05 ng/dl, TSH 1.09 μiu/ml,
untitled
RYZA IL & FAT CHEMICAL C., LTD. SAKURA EXTRACT Ver.1.4MK Ver. 1.4MK 1) 1300 1929 1 Ver. 1.4MK Sakura 1-caffeoyl---D-glucopyranoside quercetin 3---D-glucopyranoside 1) :, 4, 11-22 (1995). 2 Ver. 1.4MK 3
untitled
ORYZA POLYAMINE ORYZA POLYAMINE -P -PC -LC 1. Ver.1.0 MM ver. 1.0MM 1) Roseeuw D.I. et al., Epidermal keratinocytes actively maintain their intracellular polyamine levels. Cell Tissue Kinet. 16, 493-504
第１４〜１５回 Ｔ細胞を介する免疫系.pptx
MBL CD8 CD4 8.1 8.2 5.20 8.3 8.4 8.5 8.6 8.7 8.8 8.9 8.10 8.18 B7 CD28 CD28 B7 CD28 8.13 2.22 NK Toll(TLR) LBP! LPS dsrna ssrna TLR1/2/6! TLR4 TLR5 TLR3 TLR7/9 CD14! JNK/p38! MyD88! IRAK! TRAF! NFκB! TNF-α
Cochlear Implantations for Children with Congenital Inner Ear Malformation Ryuta Kamekura, Tomoko Shintani, Akiko Okazaki, Aya Kawabatao, Kae Kitagawa and Tetsuo Himi Department of Otolaryngology, Sapporo
CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
能書単頁9[1].5(2)
![能書単頁9[1].5(2)](/thumbs/87/96620151.jpg "能書単頁9[1].5(2)")
ips CytoTune -ips ver.1.0 1 I CytoTune ips 3 II 3 3 4 5 III CytoTune ips ips 6 6 6 6 7 1) 2) ips 8 ips 8 SeV 9 SeV 10 IV Q&A 11 V 12 12 VI...13 13...13 2 I CytoTune ips CytoTune ips 4 OCT3/4SOX2 KLF4c
Microsoft Word - 「黄砂とその健康影響について」小冊子180323版
...1...1...1...2...4...4...4...6...7...7...7...7...8...8...9...9...10... 11... 11... 11... 11...12...12...13...16...18...20 1 1-1 1-2 1 1 km 24.5 m/s 10 50 m 1 1-3 μm 1-4 1-5 2 8 http://www.jma-net.go.jp/sat/himawari/obsimg/image_dust.html
Fig.1 Chemical structure of BAY o 9867
Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985
BAANs理論に基づく保健指導プログラム暫定版
WHO 4 5 10% L- -3 RNA L - 1960-3 RNA mrna Bio Activating Advanced Nutrients BAANs BAANs BAANs BAANs L- (NO) -3 EPA, DHA) RNA RNA DNA TNF- PAI-1 ( ) BAANs 40 50% 20% 1Kg 7,000Kcal 50Kcal 11 50Kcal
1) Roth, J., Glick, S. M., Yalow, R. S. and Berson, S. A.: Hypoglycemia: A potent stimulus to secretion of growth hormone. Science, 140, 987-988, 1963. 2) Ogawa, N.: Routine Ultramicro-Measurement of Human
Fig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
日本化学療法学会雑誌第65巻第4号
Mycoplasma pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae Key words Mycoplasma pneumoniae Mycoplasma pneumoniae M. pneumoniae I M. pneumoniae M. pneumoniae M. pneumoniae
untitled
2303 16 2 9 1 14 5 31 (423) 1 (4), (6) C55H84ClN17O21S3 HCl (BLM-A2) 1487.47 11 2 1 4 104 2 14 5 31 [ ] ( ) ( ) 1. 15mg 30mg( ) 5 20mL 1 5mg( ) 2. 3 15mg 30mg( ) 5mL 1mg( ) 1mL 3. 5mg 15mg( ) 4. 1 2 1
mg 8 mg X Cr 9.84 mg/ dl K 1.5 meq/l CK 24,570 U/L Mb 79,530 ng/ml Mb 230,000 ng/ ml AKI 2 IHD IHD 4 IHD
31 1 15 20 2016 15 3 65 5 mg 8 mg 10 15 201X 7 1 11 15 Cr 9.84 mg/ dl K 1.5 meq/l CK 24,570 U/L Mb 79,530 ng/ml Mb 230,000 ng/ ml AKI 2 IHD IHD 4 IHD AKI HD 2004 48 Acute Kidney Injury AKI 48 Cr 0.3 mg/dl
mrna Zc3h12a IL-6
mrna Zc3h12a IL-6 IgG4 The 4th East Asian Group of Rheumatology (EAGOR2011) S3PE CaMK EBM PubMed NHK TBS European Thyroid Journal Nature, Lancet msv ICRP msv msv msv WHO COE sirna M M M VS VS VS
食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
DynalTransplantDiagnostic.indd
2011 1 SeCore HLA SBT 1 2 AllSet + Gold SSP HLA 7 3 SSP UniTray HLA 11 4 27 5 32 ii 1 SeCore HLA SBT SeCore 2 SeCore HLA SBT SeCore 3 SeCore 4 HLA-I 5 HLA-II 5 utype 5 GSSP 6 1 SeCore HLA SBT Sequencing
8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio
7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine
untitled
( ) - 1 - - 2 - 38% 26% A) Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma 124 (J Clin Oncol 7: 126-131, 1989) 124 95 29 II 1 2,000mg/m 2 x 4 8g/m
32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
A STUDY ON GENITAL SKIN ANDROGEN RECEPTOR BY DISPERSED CELL METHOD Yasukazu Sen and Masaaki Morioka Department of Urology, Kochi Medical School, Nankoku, Japan (Director: Prof. Yukitoshi Fujita) Yoshiteru
Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS BPD CHD 50mg100mg RS20138 RS Respiratory Syncytial Virus RS
RS Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS1998 7020021BPD 200510CHD 50mg100mg2012 812 RS20138 RS Respiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 28 2935 RS 12 6 RS BPD
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
15K00827 研究成果報告書
(TG) TG sterol regulatory element- binding protein (SREBP)-1c (Diabetes 53:560-569, 2004) SREBP-1c (1) SREBP-1c SREBP-1c liver X receptor (LXR)LXR O-Glc NAc (O-linked -N-acetyl glucosamine) (J Biol Chem
九州大学学術情報リポジトリ Kyushu University Institutional Repository 高齢心疾患患者における運動機能と身体的フレイル評価の意義 内藤, 紘一九州大学大学院人間環境学府 京都橘大学健康科学部 熊谷, 秋三九州大学大学院人間環境学府 九州大学基幹教育院 九州大
九州大学学術情報リポジトリ Kyushu University Institutional Repository 高齢心疾患患者における運動機能と身体的フレイル評価の意義 内藤, 紘一九州大学大学院人間環境学府 京都橘大学健康科学部 熊谷, 秋三九州大学大学院人間環境学府 九州大学基幹教育院 九州大学キャンパスライフ 健康支援センター https://doi.org/10.15017/1800856
CHEMOTHERAPY FEB Table 1 Background of volunteers
CHEMOTHERAPY FEB. 1985 Table 1 Background of volunteers Table 3 Reproducibility of saisomicln In the EIA and the RIA Fig.1 Comparison of the EIA with the RIA or bioassay of sisomicin Table 4 Blood levels
分子標的薬アプデート 2018
Primary imatinib, 2002-2008 (CML IV) 5-year survival 93% n = 2830 Survival probability IFN or SCT, 1997-2008 (CML IIIA) 5-year survival 71% IFN or SCT, 1995-2008 (CML III) 5-year survival 63% IFN, 1986-2003
83
Candida sppmssa Haemophilus influenzae consolidation consolidation consolidation consolidation consolidation consolidation knuckle sign Westermark sign Hampton s hump Borchardt enteropathy-associated
抗アレルギー効果のあるKW乳酸菌の発見と活用
KW3110 3 1 90 1983 6 1998 20 1989 Strachan BCG Lactobacillus Lactococcus Streptococcus Lactobacillus casei brevis johnsonii Th2 Th2 IL 4 B IgE IgE IgE IL-12 IL-12 Th1 Th1 Th2 Th2 Th1 Th2 KW 101 Th1/Th2
日本呼吸器学会雑誌第44巻第1号
β β l β β Table1 Laboratorydataonadmission Hematology WBC 9,910/μl neut 72.4% lym 20.2% eos 0.9% mon 6.1% baso 0.4% RBC 491 10 4 /μl Hb 16.8g/dl Ht 48.3% PLT 29.8 10 4 /μl ESR 3mm/hr Biochemistry TP Alb
level at age 6 in order to overcome gstagnation. h 4. A revised check-list and criteria of language ability (first plan) were made based on the above
Effect and Limit of Preschool Speech Therapy by Auditory Training Method, Aiming to Overcome gstagnation of Development at Age 9 h \ Summary of findings for 23 years \ Toshiko Mori Abstract : A retrospective
VOL. 37 NO. 3 Key words: Drug allergy, LMIT, Penams, Cephems, Cross-reactivity
VOL. 37 NO. 3 Key words: Drug allergy, LMIT, Penams, Cephems, Cross-reactivity CHEMOTHERAPY MAR. 1989 Mble 1. Allcrgy in parients nduced by penams VOL. 37 NO. 3 Table 2. Allergy in patients induced by
平成１３年度内分泌攪乱化学物質のヒトへの健康影響調査研究報告書
. 1,3 4 5. 1 2 NB-1 MCF7 MEIC 1-3 4-6 NB-1 JCRB Japan Cancer Research Bank MCF ATCCAmerican Type Culture Collection 2 19994 212 11 PVDF.22µm 8 2 11 4 4 3 5 1 4 cellsml -1 96 4,6 NB-1 48 MCF7 24 4 5 48
Correlation between molecular evolution of P450s and evolution of plant secondary metabolism Masaharu Mizutani E-mail : mizutani@scl.kyoto-u.ac.jp URL : http://biofun.kuicr.kyoto-u.ac.jp/index-j.html 13)
終末期の呼吸困難症状への対応*松坂最終修正
Clinical Question 2017 5 27 1 PCOC 1. 12778 ( 55%, 45% NRS. 1 54, 35%. NRS. NRS,,,,,,,, Performance status, Ekstrom, M., et al.2016 J Pain Symptom Manage 51(5):816-23. . 1 85 ADL. 3,,,,. JCS200,, 40 /,
Rinku General Medical Center
Rinku General Medical Center 4860 100 1620 Ann Intern Med. 1966; 64: 328 40 CHOP 63 1 83 J Clin Oncol. 1998; 16: 20065-69 Febrile Neutropenia IDSA(Infectious Diseases Society of America) 2002 Guidelines
sick contact1l
Clinical Question 2017 年 5 月 15 日 分野 : 内分泌テーマ : 治療 19 14 15 18 sick contact1l 170cm/68.8kg, GCSE1V1M5, HR: 120/min, BP: 104/60mmHg, RR: 30/min, SpO 2 : 96%, BT: 38.0 WBC Hb PLT CRP Cr BUN 23400 15.0 35.5
A study on thyroid function in patients on chronic dialysis Masahumi Kikkawa, Issei Tanaka, Naoki Haruta, Takao Hinoi, Tamaki Nakatani, Kazuaki Miyamo
A study on thyroid function in patients on chronic dialysis Masahumi Kikkawa, Issei Tanaka, Naoki Haruta, Takao Hinoi, Tamaki Nakatani, Kazuaki Miyamoto Artifical Kidney Center, Hiroshima Prefectural Hiroshima
L
-G -VG -G -VG.MPa..MPa.1MPa..MPa 1.5MPa 1.5MPa 1.5MPa 1.5MPa 1 s 5 5 - -V 1.51MPa 1.5MPa s s..mpa.mpa 1.5MPa 1.5MPa - -V 1 s s 5 5 1 JISg/H 1. 1.5. 11 SLLBFFB SLLBFTC CCCCBTC..MPa 1.5MPa SLLBFFB CCCCBTC
Recurrent Vertigo with Unilateral or Bilateral Sensorineural Hearing Loss of Unkown Etiology. Tsutomu Yamazaki, Sachie Watanabe, Hideo Kozaki and Taka
Recurrent Vertigo with Unilateral or Bilateral Sensorineural Hearing Loss of Unkown Etiology. Tsutomu Yamazaki, Sachie Watanabe, Hideo Kozaki and Takao Abe (Sapporo General Hosp.) Kazuo Yamamoto (Tomakomai)
日本消化器外科学会雑誌第30巻第3号
Key words : gastric cancer, progltostic factor. multivariate analysis Factors selected after Coffelation- after Stepwise rnitrally check check H o s t l A g e C O 2 S e x C O 3 Pre-op. compliation O Treatment
49-4 ™ñ„¾ Œ]„”†i4†j
![49-4 ™ñ„¾ Œ]„”†i4†j](/thumbs/91/107437840.jpg "49-4 ™ñ„¾ Œ]„”†i4†j")
Current Topics in Diagnostic Imaging of the Pediatric Neck Eiji Oguma, M.D. Department of Radiology, Saitama Children s Medical Center NICHIDOKU-IHO Vol. 49 No. 4 61 83 (2004) Summary This article focuses
1
I II II 1 dw = pd = 0 1 U = Q (4.10) 1K (heat capacity) (mole heat capacity) ( dq / d ) = ( du d C = / ) (4.11) du = C d U = C d (4.1) 1 1 du = dq + dw dw = pd dq = du + pd (4.13) p dq = d( U + p ) p (4.14)